Financials in USD. Standardized financial statements.
A compact view of how Rapid Micro Biosystems, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $33.59M | $28.05M | $22.52M | $17.13M | $23.23M | $16.08M | $16.51M |
| Revenue Growth? | +19.7% | +24.6% | +31.4% | -26.3% | +44.5% | -2.6% | 0.0% |
| Cost of Revenue? | $25.98M | $28.16M | $28.00M | $25.67M | $30.97M | $24.15M | $16.75M |
| Gross Profit? | $7.61M | -$109,000 | -$5.49M | -$8.54M | -$7.74M | -$8.07M | -$234,000 |
| Gross Margin? | +22.7% | -0.4% | -24.4% | -49.8% | -33.3% | -50.2% | -1.4% |
| Operating Expenses? | $55.00M | $49.81M | $51.08M | $54.68M | $39.49M | $22.47M | $18.40M |
| Operating Income? | -$47.39M | -$49.92M | -$56.56M | -$63.22M | -$47.23M | -$30.54M | -$18.63M |
| EBITDA? | -$44.14M | -$46.56M | -$53.46M | -$60.38M | -$45.70M | -$32.00M | -$16.87M |
| Income Before Tax | -$47.08M | -$46.87M | -$52.44M | -$61.38M | -$73.43M | -$36.94M | -$20.74M |
| Income Tax Expense | $40,000 | $22,000 | $31,000 | -$576,000 | $91,000 | $134,000 | $427,000 |
| Net Income? | -$47.12M | -$46.89M | -$52.47M | -$60.81M | -$73.52M | -$37.08M | -$21.17M |
| EPS? | $-1.05 | $-1.08 | $-1.22 | $-1.43 | $-1.88 | $-1.17 | $-0.53 |
| Diluted EPS? | $-1.05 | $-1.08 | $-1.22 | $-1.43 | $-1.88 | $-1.17 | $-0.53 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality